6 months ago
BB2121 CAR-T(Abecma、Idecabtagene Vicleucel、ide-cel) BB2121 CAR-T, now known as Abecma, Idecabtagene Vicleucel, or ide-cel. Bluebird bio initially designed and compared four second-generation anti...
6 months ago
CAR-T Abecma Multiple Myeloma Treatment Increases PFS by More Than Three Times, and CAR-T Cell Therapy Targeting BCMA has been re Approved by the FDA Bristol Myers Squibb and 2seventy bio recently ...
6 months ago
China’s First CAR-T Trial: “Pay-for-Performance” Introduced! CAR-T China has taken a groundbreaking step towards pay-for-performance! Fosun Kite announces an exciting initi...
6 months ago
Abecma (Ideabtagene Vicleucel) FDA Approval Date and Brief Introduction of Drugs Overview of FDA Approval of Abecma On March 26, 2021, Abecma® (Idecabtagene Vicleucel, ide-cel) received approval fr...
6 months ago
On August 19, 2021, Abecma(Idecabtagene Vicleucel) Granted EMA Approval in the EU for the Treatment of Relapsed and Refractory Multiple Myeloma Abecma Approved for Marketing in Europe On August 19,...
6 months ago
On April 4, 2024,Abecma® (Idecabtagene Vicleucel) FDA Approval for the Treatment of Relapsed or Refractory Multiple Myeloma On April 4th, 2024, Abecma® (idecabtagene vicleucel) received approval fr...
6 months ago
Can Myeloma CAR-T Cell Therapy Achieve Cure? Multiple Myeloma (MM) is a monoclonal plasma cell malignant proliferative tumor, accounting for approximately 10% of hematological malignancies. Cytogen...
6 months ago
Introducing the Momentum of the Next-Generation “Pan-Cancer” Targeted Therapy ICP-723 of China Pan-Cancer ICP-723 On April 11, 2022, InnoCare Pharma unveiled the preclinical data ...
6 months ago
The world’s first #CART therapy approved for second-line treatment of multiple myeloma is claimed by a Chinese pharmaceutical company Mutiple myeloma #Legend Biotech How to advance #CARTc...
6 months ago
Carvykti Target is BCMA, Brief Introduction of BCMA Target Carvykti Target is BCMA BCMA (B-Cell Maturation Antigen) is a specific target for multiple myeloma, and therapies targeting BCMA are consi...
6 months ago
GPRC5D Targeted CAR-T Cells for Myeloma In addition to serving as an antibody target, GPRC5D is a promising CAR target. Introduction to a CART targeting GPRC5D. Main Content Early clinical results...
6 months ago
Overview of BCMA in Multiple Myeloma CAR-T Cell Therapy Introduction to BCMA BCMA (B-cell maturation antigen) is considered a major target for the treatment of multiple myeloma. Currently, the thre...
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
© Copyright 2023 Advanced Medicine In China. All rights reserved.
